The most advanced oncology therapeutic decision platform
OmiCure® helps oncologists and other practitioners choose optimal therapeutics for each patient by providing a personalized selection of existing treatments.
OmiCure® goes beyond standard DNA analysis by including the differential analysis of RNA expression in tumors. OmiCure® benefits from multiple international collaborations with leading personalized medicine consortia, including some of the world’s most renowned clinical centers.Discover the results of WINTHER Trial
OmiCure® uses an explainable Artificial Intelligence (xAI) technology to identify the ability of existing drugs to fight your specific tumor.
OmiCure® has the potential to revolutionize the effectiveness of cancer therapy, enabling the choice of the right treatment for the right patient, improving outcomes, avoiding unnecessary side effects as well as decreasing treatment costs.
OmiCure® matches the tumor's genomic signature with a massive database gathering available data from scientific publication and clinical trials worldwide, compiling more than forty thousands of chemical–disease associations, from multiple sources, including public databases, or proprietary academic-industry consortia
OmiCure® uses RNA data.
This approach was tested and validated through the WINTHER clinical trial. The results of this trial were published in Nature Medicine in April 2019. For the first time in a clinical setting, the WINTHER trial applied transcriptomics (gene expression) to guide decision. Using transcriptional analysis that specifically compared tumor to matched normal tissue, the trial was able to bring personalized cancer treatments to a greater number of patients.